Wealth management, Investment World, Investment, Stocks, Money, Insurance, Bonds - The Hindu BusinessLine

portfolio

SHAILESH ANDRADE

L&T Q1 FY24 review: Margin pressure in core infra segment persists

Tata Steel: European operations holds back domestic progress

Amidst the frenzy in small-caps, fund managers aren’t rushing to deploy cash

Pharma companies see decade-high success rates in USFDA audits

Dr Lal PathLabs, Metropolis and Thyrocare: Why shares underperformed last year and should you buy now?

Do you own any of the best-performing stock SIPs? Find out here

Market-beating mirage: Stock SIPs fall short of great expectations

Lupin’s gSpiriva approval: Good addition, but factored into valuations

While Indian bond investors cheer, global counterparts grapple with volatility, losses, and uncertainty

The spike in global bond yields comes with risks of igniting unknown factors

By Hari Viswanath

Glenmark Pharma sale of Glenmark Life Sciences: What it means for investors?

Positive drivers

Rupee stable despite shrinking yield gap

Aeroflex IPO: Key things to know and should you subscribe?

India, US, Germany, UK, France, Japan and China: Insights from IMF database on debt in major economies

Today’s Poll

bl21_ndanm_DMKw+GKK1F5DRS.3.jpg.jpg

Will the Women’s Reservation Bill bring gender equality to the Parliament?

Revising strategy

How gencos are readying for energy transition

Adani’s acquisition of Sanghi Industries: Is the premium paid by Ambuja justified?

Cipla and Dr. Reddy Q1FY24 results highlight tailwinds for pharma sector

Sign into Unlock benefits!

Access 10 free stories per month
Access to comment on every story
Sign up/Manage to our newsletters
Get notified by email for early preview to new features, discounts & offers